Football photos: St. John Vianney at Pope John, Non-Public B semis, Nov. 23, 2024Private banks outrun public sector peers in priority lending benchmarksThe Sacramento Kings are navigating a difficult start to the 2024-25 season. Under Mike Brown, the Kings are now viewed as a legitimate postseason threat in the Western Conference. However, injuries and poor production have seen the Kings stutter toward a 10-13 record. Not much has changed with the Kings roster between last season and now, except for the addition of DeMar DeRozan on a sign-and-trade deal this summer. Since joining the Kings, the veteran forward is averaging 22.7 points, 4.2 rebounds and 4.2 assists. He's shooting 49.7% from the field and 28.9% from three-point range. According to an anonymous NBA executive who spoke with ESPN's Brian Windhorst and Tim Bontemps, DeRozan doesn't bring a winning style of basketball to the equation. “DeRozan is a highly skilled player who is great to have in the locker room and a guy who you want to give the ball to at the end of a game," the executive said. "But his play hasn't driven winning, and it's something that unfortunately has been the case throughout his career and it's part of why he's changed teams a bunch.” There's no denying that DeRozan's skill set is somewhat of a throwback. He isn't a perimeter threat, and he thrives in the mid-range, which is consistently devalued in the modern game. However, he has been a picture of consistency throughout his career. Blaming him for his team's not winning a championship is disingenuous. Furthermore, the executive's comments now provide the Kings with a pathway to using DeRozan as a scapegoat if their season continues to go sideways. If the veteran isn't perceived to be playing winning basketball, it becomes easy to point the finger and absolve the front office and coaching staff of blame. DeRozan chose to join the Kings. He was one of the hottest free agents on the market. The fact that so many front offices wanted to add him to their roster speaks volumes about the impact he can have on the floor. He's too good to be used as a potential scapegoat. If his fit in Sacramento isn't working, they should explore potential trades closer to the Feb. 6 deadline. Having an anonymous executive claim you don't play 'winning' basketball is bad enough. Let's hope that it doesn't lead to DeRozan's reputation being questioned as a result. After all, he's been in the NBA for 16 seasons. His body of work speaks for itself.Published 6:30 pm Tuesday, November 26, 2024 By Data Skrive Our best bet against the spread on the NFL’s Week 13 card is Chargers -1.5 — keep reading for more suggestions (including parlay opportunities) for both spreads and over/unders. Catch every NFL touchdown with NFL RedZone on Fubo. Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER .
Separated from their kids, this Dakelh couple journeyed across ‘B.C.’ for justiceTowards Autonomous Surface Missions on Ocean Worlds
Has the Robotics Revolution Arrived?My Experience With Miracle Smile Magic Flosser – Trusted Review 2024
BUENOS AIRES (AP) — Thiago Messi, the eldest son of the Argentina star, has made his debut in the “Newell’s Cup” tournament in the countryside city of Rosario. The 12-year-old Messi played with the No. 10 jersey of an Inter Miami youth team, which lost 1-0 on Monday to host Newell’s Old Boys in the traditional under-13 competition. The team also played Tuesday. Lionel Messi took his first steps as a footballer in the Argentinian club in Rosario, 300 kilometers (186 miles) northwest of capital Buenos Aires. Thiago's mother, Antonela Roccuzzo, and several members of his family, including grandparents Jorge Messi and Celia Cuccittini, were in the stands to watch him play. Lionel Messi did not attend. Thiago, who was substituted in the second half, played with his friend Benjamín Suárez, son of Uruguayan striker Luis Suárez, Messi's teammate and close friend at Barcelona and now at Inter Miami. Messi and Suárez are in Rosario after Inter Miami’s early elimination in the MLS playoffs. On Sunday, they watched a friendly game of Inter Miami's U13 team against Unión at the same sports complex. The youth tournament in Argentina brings together eight teams from North and South America. AP soccer: https://apnews.com/hub/soccerMMA star Cecilie Bolander broke down in tears after winning her title fight - despite the sport being ILLEGAL in her country. Bolander is from Norway, where professional MMA is BANNED 2 Cecilie Bolander became Oktagon MMA champion Credit: oktagon mma Since 1981, all sports involving knockouts as a method of victory were outlawed - but it was lifted for boxing in 2014. MMA though is still not recognised - meaning Norwegian fighters are forced to travel abroad to compete. Bolander is one of them but she will now return home as a champion after beating Lucie Pudilova for the bantamweight Oktagon title. The 28-year-old broke down in tears as she emotionally called for the sport to be legalised in her homeland. READ MORE IN MMA MODEL PRO Meet the MMA star proposed in cage with a broken foot and fights in €1 final She screamed: "Please legalise the sport in Norway!" Bolander only began fighting in 2021 and made her pro debut a year later. She is now 4-1 after defeating Pudilova in their rematch - having lost to her in September. Bolander ran around the cage after her split-decision win was announced. Most read in MMA NO GLOVE LOST UFC fans all say same thing after seeing McGregor's latest training video WHITE ON TRACK Dana White reveals wheels are in motion for 'biggest fight in UFC history' MAC OUT Rogan reveals why UFC legend McGregor's career could be over, despite return plea PAIN GAME 'My thing looked weird... I felt absurd pain' - Ex-UFC star fractures penis CASINO SPECIAL - BEST CASINO BONUSES FROM £10 DEPOSITS And failing to fight back tears, she said: "This is hard! I didn't plan on five rounds, I'm sorry. "I work for five rounds but you always want the fast finish. I hope we gave you entertainment, I love that part of the sport. "What I was going to say in the beginning was I really, really appreciate Oktagon for taking me in like you have. "For the fans that's been supporting me from the last fight, I'm forever grateful. 2 The Norwegian broke down in tears after victory Credit: oktagon mma "I love this sport with all my heart - it's a really f***ing hard sport but it makes it was easier when we have fans like you guys. I'm very emotional guys, you'll get used to it! "Pudilova, thank you for the amazing fight, to my team I love you to the bottom of my heart for all you've been through with me. "To my friends and family and team-mates at Norwegian Top Team, you guys are my brothers and I love you for that, for always having my back."
PARIS -- French President Emmanuel Macron vowed Thursday to stay in office until the end of his term, due in 2027, and announced that he will name a new prime minister within days in efforts to overcome the political deadlock following the resignation of ousted Prime Minister Michel Barnier . Macron came out fighting a day after a historic no-confidence vote prompted by budget disputes at the National Assembly left France without a functioning government. He laid blame at the door of his opponents on the far right for bringing down Barnier's government. “They chose disorder,” he said. The president said the far right and the far left had united in what he called “an anti-Republican front” and stressed: “I won’t shoulder other people’s irresponsibility.” He said he’d name a new prime minister within days but gave no hints as to who that might be. Earlier in the day, Macron “took note” of Barnier’s resignation after just three months in office — the shortest tenure of any prime minister in modern French history. While critical of his political opponents, Macron also acknowledged what he described as his own responsibility in the chaos now shaking French politics and alarming financial markets. He revisited his decision in June to dissolve parliament. That precipitated the crisis, leading to legislative elections that produced the now hung parliament , divided between three minority blocs that do not have enough seats to govern alone. “I do recognize that this decision wasn’t understood. Many criticized me for it,” Macron said. However, he argued, “I believe it was necessary” to let French voters speak. Macron said the new prime minister “will be charged with forming a government of general interest." He confirmed that a special law will be presented by mid-December to enable the state to levy taxes from Jan. 1, based on this year’s rules, and avoid a shutdown. “Public services will be operational, businesses will be able to work,” he said. The new government will then prepare a budget law for 2025, which will allow France to invest as planned in its military, its justice and police — and also to support struggling farmers, Macron said. Along with its own domestic political and financial difficulties — not least France’s ballooning levels of debt — Macron noted that the country faces multiple international challenges, citing the wars in Ukraine and Middle East . He looked back at the Paris Olympics in July-August and ahead to the reopening this weekend of Notre Dame Cathedral , arguing that France can emerge from this latest political crisis if it sets its mind on it. “It’s proof that we know how to do great things, that we know how to achieve the impossible," he said. "Twice this year, the world has admired us for this,” he said, referring to the hosting of the Olympics and the restoration of Notre Dame. “Well, for the nation, we must do same thing.” Macron faces the critical task of naming a replacement for Barnier capable of leading a minority government in a parliament where no party holds a majority. Yaël Braun-Pivet, president of the National Assembly and a member of Macron’s party, urged the president to move quickly. “I recommend he decide rapidly on a new prime minister,” Braun-Pivet said Thursday on France Inter radio. “There must not be any political hesitation. We need a leader who can speak to everyone and work to pass a new budget bill.” The process may prove challenging. French media have reported a shortlist of centrist candidates who might appeal to both sides of the political spectrum. The no-confidence vote has galvanized opposition leaders, with some explicitly calling for Macron’s resignation. “I believe that stability requires the departure of the President of the Republic,” Manuel Bompard, leader of the far-left France Unbowed party, said on BFM TV Wednesday night. Far-right National Rally leader Marine Le Pen , whose party holds the most seats in the Assembly, stopped short of calling for Macron’s resignation but warned that “the pressure on the President of the Republic will get stronger and stronger.” The French constitution does not call for a president to resign after his government was ousted by the National Assembly. It also says that new legislative elections cannot be held until at least July, creating a potential stalemate for policymakers. The political instability has heightened concerns about France’s economy, particularly its debt , which could rise to 7% of GDP next year without significant reforms. Analysts say that Barnier's government downfall could push up French interest rates, digging the debt even further. Rating agency Moody’s warned late Wednesday that the government’s fall “reduces the likelihood of consolidating public finances” and worsens the political gridlock. A planned protest by teachers against budget cuts in education took on a new tone Thursday, as demonstrators in Paris linked their demands to the political crisis. “Macron quit!” read a sign held by Dylan Quenon, a 28-year-old teacher at a middle school in Aubervilliers, just north of Paris. Quenon said Macron bears responsibility for what he described as the dismantling of public services such as schools. “The only way for this to change is to have him out of office,” he said. Protesters expressed little hope that Macron’s next appointee would reverse course. “I’m glad this government is falling, but it could possibly lead to something even worse,” said Élise De La Gorce, a 33-year-old teacher in Stains, north of Paris.
BUENOS AIRES (AP) — Thiago Messi, the eldest son of the Argentina star, has made his debut in the “Newell’s Cup” tournament in the countryside city of Rosario. The 12-year-old Messi played with the No. 10 jersey of an Inter Miami youth team, which lost 1-0 on Monday to host Newell’s Old Boys in the traditional under-13 competition. The team also played Tuesday. Lionel Messi took his first steps as a footballer in the Argentinian club in Rosario, 300 kilometers (186 miles) northwest of capital Buenos Aires. Thiago's mother, Antonela Roccuzzo, and several members of his family, including grandparents Jorge Messi and Celia Cuccittini, were in the stands to watch him play. Lionel Messi did not attend. Thiago, who was substituted in the second half, played with his friend Benjamín Suárez, son of Uruguayan striker Luis Suárez, Messi's teammate and close friend at Barcelona and now at Inter Miami. Story continues below video Messi and Suárez are in Rosario after Inter Miami’s early elimination in the MLS playoffs. On Sunday, they watched a friendly game of Inter Miami's U13 team against Unión at the same sports complex. The youth tournament in Argentina brings together eight teams from North and South America. AP soccer: https://apnews.com/hub/soccerGeorgia QB Carson Beck takes hit on throwing arm before halftime, leaving status uncertain
EU Nears Final Push for South American Trade Deal Despite France ProtestsAP Sports SummaryBrief at 6:28 p.m. EST‘ASI who saved Sukhbir wasn’t on duty’
What Is Mocha Mousse, the First-Ever Shade of Brown Chosen as Pantone's Color of the Year?
I’m a fashion stylist and I can NEVER shop at TK Maxx after spotting a major problem – you won’t un-see it either
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenGeorgia QB Carson Beck takes hit on throwing arm before halftime, leaving status uncertainIn the current session, the stock is trading at $74.10, after a 0.78% spike. Over the past month, Banner Inc. BANR stock increased by 2.24% , and in the past year, by 51.96% . With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued. Evaluating Banner P/E in Comparison to Its Peers The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. Compared to the aggregate P/E ratio of the 25.32 in the Banks industry, Banner Inc. has a lower P/E ratio of 15.38 . Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
